VERAXA Biotech (NASDAQ: VRXA) has released new in vitro proof-of-concept data demonstrating the potential of its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA's BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results suggest that VERAXA's proprietary BiTAC approach could enhance the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
VERAXA's diversified oncology pipeline includes antibody-based formats such as ADCs, T-cell engagers (TCEs), and other antibody-based formats. The company recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.
The announcement comes as VERAXA prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026. The company is seeking collaborations to advance its BiTAC-ADC and BiTAC-TCE platforms, which aim to address limitations in current cancer therapies by improving tumor targeting and reducing off-target effects.
For more information on VERAXA Biotech, visit the company's newsroom at https://ibn.fm/VRXA.
